近日，乐普生物自主研发的表皮生长因子受体（EGFR）靶向创新型抗体药物偶联物（ADC）——注射用维贝柯妥塔单抗（商品名：美佑恒®），已正式获得国家药品监督管理局（NMPA）附条件批准上市，用于治疗既往经至少二线系统化疗和PD-1/PD-L1抑制剂治疗失败的复发/转移性鼻咽癌的成人患者。作为全球首款获批上市的EGFR靶向ADC药物，维贝柯妥塔单抗为相关患者提供了全新的治疗选择。鼻咽癌——具有鲜明“...
Source Link近日，乐普生物自主研发的表皮生长因子受体（EGFR）靶向创新型抗体药物偶联物（ADC）——注射用维贝柯妥塔单抗（商品名：美佑恒®），已正式获得国家药品监督管理局（NMPA）附条件批准上市，用于治疗既往经至少二线系统化疗和PD-1/PD-L1抑制剂治疗失败的复发/转移性鼻咽癌的成人患者。作为全球首款获批上市的EGFR靶向ADC药物，维贝柯妥塔单抗为相关患者提供了全新的治疗选择。鼻咽癌——具有鲜明“...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.